Announced details
Cancer supportive care, regardless of the presence or absence of radiation-induced lung injury (RILI) or immune checkpoint inhibitor-related pneumonitis (CIP)
Enrollment of the first participant was completed in April 2026 (Phase 2/3 clinical trial)
Gyre Pharmaceuticals Co., Ltd. is a consolidated subsidiary of the company and is developing the pirfenidone capsules in-house.
The impact of progress in this clinical trial on the company's consolidated results is expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pirfenidone capsules (product name: Esbriet) |
| Relationship with the Company | Gyre Pharmaceuticals Co., Ltd. is a consolidated subsidiary of the company and is developing the pirfenidone capsules in-house. |
| Applicable area | Cancer supportive care, regardless of the presence or absence of radiation-induced lung injury (RILI) or immune checkpoint inhibitor-related pneumonitis (CIP) |
| Usage history | Enrollment of the first participant was completed in April 2026 (Phase 2/3 clinical trial) |
| Impact on Business Performance | The impact of progress in this clinical trial on the company's consolidated results is expected to be minor. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company aims to expand pirfenidone's indications to radiation-induced lung injury and broaden treatment options.